PCSK9 and lung carcinoma: In our IVW analyses, PCSK9 inhibitors showed significant protective effects against breast and lung cancers (OR = 0.9, 95%CIbreast cancer: 0.81~0.99; p = 2.25 × 10−2; OR = 0.79, 95%CIlung cancer: 0.65~0.94, p = 2.55 × 10−3, Figure 2).